MIEN1 is Tightly Regulated by SINE Alu Methylation in Its Promoter

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Sep 3

PMID 27589566

Citations 6

Authors

Smrithi Rajendiran

Lee D Gibbs

Timothy Van Treuren

David L Klinkebiel

Jamboor K Vishwanatha

Affiliations

Soon will be listed here.

Abstract

Migration and invasion enhancer 1 (MIEN1) is a novel gene involved in prostate cancer progression by enhancing prostate cancer cell migration and invasion. DNA methylation, an important epigenetic regulation, is one of the most widely altered mechanisms in prostate cancer. This phenomenon frames the basis to study the DNA methylation patterns in the promoter region of MIEN1. Bisulfite pyrosequencing demonstrates the MIEN1 promoter contains a short interspersed nuclear Alu element (SINE Alu) repeat sequence. Validation of methylation inhibition on MIEN1 was performed using nucleoside analogs and non-nucleoside inhibitors and resulted in an increase in both MIEN1 RNA and protein in normal cells. MIEN1 mRNA and protein increases upon inhibition of individual DNA methyltransferases using RNA interference technologies. Furthermore, dual luciferase reporter assays, in silico analysis, and chromatin immunoprecipitation assays identified a sequence upstream of the transcription start site that has a site for binding of the USF transcription factors. These results suggest the MIEN1 promoter has a SINE Alu region that is hypermethylated in normal cells leading to repression of the gene. In cancer, the hypomethylation of a part of this repeat, in addition to the binding of USF, results in MIEN1 expression.

Citing Articles

Insertion of 643bp Retrotransposon Upstream of CDS Is Associated with Backfat of Large White Pigs.

He J, Yu M, Chi C, Du Z, Zheng Y, Chen C Animals (Basel). 2023; 13(14).

PMID: 37508132 PMC: 10376311. DOI: 10.3390/ani13142355.

Origin, evolution, and tissue-specific functions of the porcine repetitive element 1.

Zheng M, Guo T, Yang B, Zhang Z, Huang L Genet Sel Evol. 2022; 54(1):54.

PMID: 35896967 PMC: 9327148. DOI: 10.1186/s12711-022-00745-3.

Tissue and cancer-specific expression of DIEXF is epigenetically mediated by an Alu repeat.

Martin B, Pappa S, Diez-Villanueva A, Mallona I, Custodio J, Barrero M Epigenetics. 2020; 15(6-7):765-779.

PMID: 32041475 PMC: 7574385. DOI: 10.1080/15592294.2020.1722398.

Migration and Invasion Enhancer 1 Is an NF-ĸB-Inducing Gene Enhancing the Cell Proliferation and Invasion Ability of Human Prostate Carcinoma Cells In Vitro and In Vivo.

Chang K, Tsui K, Lin Y, Hou C, Feng T, Juang H Cancers (Basel). 2019; 11(10).

PMID: 31581708 PMC: 6826896. DOI: 10.3390/cancers11101486.

Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis.

Kushwaha P, Gupta S, Singh A, Kumar S Front Oncol. 2019; 9:868.

PMID: 31552186 PMC: 6738349. DOI: 10.3389/fonc.2019.00868.

References

Medvedeva Y, Khamis A, Kulakovskiy I, Ba-Alawi W, Bhuyan M, Kawaji H . Effects of cytosine methylation on transcription factor binding sites. BMC Genomics. 2014; 15:119. PMC: 3986887. DOI: 10.1186/1471-2164-15-119. View

Vestergaard E, Nexo E, Torring N, Borre M, Orntoft T, Sorensen K . Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int J Cancer. 2010; 127(8):1857-65. DOI: 10.1002/ijc.25209. View

Evans E, Henn A, Jonason A, Paris M, Schiffhauer L, Borrello M . C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Mol Cancer Ther. 2006; 5(11):2919-30. DOI: 10.1158/1535-7163.MCT-06-0389. View

West A, Huang S, Gaszner M, Litt M, Felsenfeld G . Recruitment of histone modifications by USF proteins at a vertebrate barrier element. Mol Cell. 2004; 16(3):453-63. DOI: 10.1016/j.molcel.2004.10.005. View

Kpetemey M, Dasgupta S, Rajendiran S, Das S, Gibbs L, Shetty P . MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Mol Cancer. 2015; 14:156. PMC: 4536591. DOI: 10.1186/s12943-015-0428-8. View

Christman J . 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002; 21(35):5483-95. DOI: 10.1038/sj.onc.1205699. View

Dasgupta S, Wasson L, Rauniyar N, Prokai L, Borejdo J, Vishwanatha J . Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene. 2009; 28(32):2860-72. PMC: 2726905. DOI: 10.1038/onc.2009.145. View

Weinstein J, Collisson E, Mills G, Mills Shaw K, Ozenberger B, Ellrott K . The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45(10):1113-20. PMC: 3919969. DOI: 10.1038/ng.2764. View

Holliday R . The inheritance of epigenetic defects. Science. 1987; 238(4824):163-70. DOI: 10.1126/science.3310230. View

10.

Singh N, Duenas-Gonzalez A, Lyko F, Medina-Franco J . Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem. 2009; 4(5):792-9. DOI: 10.1002/cmdc.200900017. View

11.

Cho N, Kim B, Choi M, Yoo E, Moon K, Cho Y . Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 2006; 211(3):269-77. DOI: 10.1002/path.2106. View

12.

Hasler J, Strub K . Alu elements as regulators of gene expression. Nucleic Acids Res. 2006; 34(19):5491-7. PMC: 1636486. DOI: 10.1093/nar/gkl706. View

13.

Dasgupta S, Cushman I, Kpetemey M, Casey P, Vishwanatha J . Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. J Biol Chem. 2011; 286(29):25935-46. PMC: 3138290. DOI: 10.1074/jbc.M111.254599. View

14.

Aryee M, Jaffe A, Corrada-Bravo H, Ladd-Acosta C, Feinberg A, Hansen K . Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30(10):1363-9. PMC: 4016708. DOI: 10.1093/bioinformatics/btu049. View

15.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

16.

Zhang W, Edwards A, Fan W, Deininger P, Zhang K . Alu distribution and mutation types of cancer genes. BMC Genomics. 2011; 12:157. PMC: 3074553. DOI: 10.1186/1471-2164-12-157. View

17.

Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J . Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007; 26(45):6560-5. DOI: 10.1038/sj.onc.1210472. View

18.

Ehrlich M . DNA methylation in cancer: too much, but also too little. Oncogene. 2002; 21(35):5400-13. DOI: 10.1038/sj.onc.1205651. View

19.

Baylin S . DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005; 2 Suppl 1:S4-11. DOI: 10.1038/ncponc0354. View

20.

Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A . Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res. 2003; 9(5):1596-603. View